NO20093488L - Biomarkorer for a predikere anti-TNF respons eller ikke-respons - Google Patents

Biomarkorer for a predikere anti-TNF respons eller ikke-respons

Info

Publication number
NO20093488L
NO20093488L NO20093488A NO20093488A NO20093488L NO 20093488 L NO20093488 L NO 20093488L NO 20093488 A NO20093488 A NO 20093488A NO 20093488 A NO20093488 A NO 20093488A NO 20093488 L NO20093488 L NO 20093488L
Authority
NO
Norway
Prior art keywords
response
tnf
biomarkers
predicting anti
person
Prior art date
Application number
NO20093488A
Other languages
English (en)
Norwegian (no)
Inventor
Jadwiga Bienkowska
John P Carulli
Peter K Gregersen
Franak Batliwalla
Chunyu Liu
Original Assignee
The Feinstein Inst Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Feinstein Inst Medical Res filed Critical The Feinstein Inst Medical Res
Publication of NO20093488L publication Critical patent/NO20093488L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
NO20093488A 2007-06-08 2009-12-08 Biomarkorer for a predikere anti-TNF respons eller ikke-respons NO20093488L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94293707P 2007-06-08 2007-06-08
PCT/US2008/066180 WO2008154423A2 (en) 2007-06-08 2008-06-06 Biomarkers for predicting anti-tnf responsiveness or non-responsiveness

Publications (1)

Publication Number Publication Date
NO20093488L true NO20093488L (no) 2010-01-08

Family

ID=40130456

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20093488A NO20093488L (no) 2007-06-08 2009-12-08 Biomarkorer for a predikere anti-TNF respons eller ikke-respons

Country Status (16)

Country Link
US (1) US20100303813A1 (de)
EP (2) EP2167687B1 (de)
JP (2) JP5719591B2 (de)
KR (1) KR20100037590A (de)
CN (2) CN101796197B (de)
AU (1) AU2008261869B2 (de)
BR (1) BRPI0812461A2 (de)
CA (1) CA2690898A1 (de)
EA (1) EA017815B1 (de)
IL (2) IL202562A0 (de)
MX (1) MX2009013410A (de)
NO (1) NO20093488L (de)
NZ (1) NZ581742A (de)
SG (1) SG182183A1 (de)
WO (1) WO2008154423A2 (de)
ZA (1) ZA200909215B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090235713A1 (en) * 2008-03-24 2009-09-24 Hirotec America, Inc. Magnetically actuated roller head
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US8512964B2 (en) 2008-12-12 2013-08-20 The Regents Of The University Of California Targets for treatment of hypercholesterolemia
JP4883117B2 (ja) * 2009-03-23 2012-02-22 コニカミノルタビジネステクノロジーズ株式会社 画像処理装置の課金装置、それを用いた画像処理装置、画像処理装置の課金装置の制御方法、及び画像処理装置の課金装置の制御プログラム
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
EP3211094A3 (de) 2009-09-03 2017-11-01 F. Hoffmann-La Roche AG Verfahren zur behandlung, diagnose und überwachung rheumatoider arthritis
RU2012139181A (ru) 2010-02-26 2014-04-10 Ново Нордиск А/С Стабильная композиция, содержащая антитело
WO2011117366A2 (en) * 2010-03-24 2011-09-29 Tc Land Expression Genes and genes combinations predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd)
MX2012013586A (es) 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
BR112013021725A2 (pt) 2011-02-28 2016-11-01 Genentech Inc marcadores biológicos e métodos para prever resposta aos antagonistas de células b
CA2864133A1 (en) 2012-02-10 2013-08-15 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
US9031292B2 (en) * 2012-04-19 2015-05-12 Chang Gung University Method for the diagnosis of neurodegenerative disorder by using diffusion kurtosis imaging
EP2861767A4 (de) * 2012-06-15 2016-07-27 Nuclea Biotechnologies Inc Prädiktive marker für krebs und stoffwechselsyndrom
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
ES2524164B1 (es) * 2013-05-03 2015-10-27 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Pronóstico de respuesta al tratamiento con anti-tnfalfa en pacientes de artritis reumatoide
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
WO2016040861A1 (en) * 2014-09-12 2016-03-17 Biogen Ma Inc. Systems and methods for characterization of multiple sclerosis
EP3770274A1 (de) 2014-11-05 2021-01-27 Veracyte, Inc. Systeme und verfahren zur diagnose von idiopathischer pulmonaler fibrose auf transbronchialen biopsien mit maschinellem lernen und hochdimensionalen transkriptionsdaten
US10098168B2 (en) * 2014-12-08 2018-10-09 Apple Inc. Neighbor awareness networking datapath
GB2547406A (en) * 2015-11-20 2017-08-23 Folkersen Lasse Apparatus and methods of using of biomarkers for predicting TNF-inhibitor response
SMT202300314T1 (it) 2015-12-03 2023-11-13 Regeneron Pharma Metodi di associazione di varianti genetiche con esito clinico in pazienti affetti da degenerazione maculare senile trattati con anti-vegf
GB201521357D0 (en) * 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
CN106520771B (zh) * 2016-12-20 2019-02-12 江苏省人民医院 一种长非编码rna及其在诊断/治疗子痫前期中的应用
EP4467565A3 (de) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf-alpha-antikörperformulierungen
KR102094802B1 (ko) * 2017-10-24 2020-03-31 고려대학교 산학협력단 소변 대사체 분석을 이용한 베체트병의 진단방법
WO2019178546A1 (en) * 2018-03-16 2019-09-19 Scipher Medicine Corporation Methods and systems for predicting response to anti-tnf therapies
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN110141578B (zh) * 2019-06-10 2022-06-14 南通大学 环状RNA circ-Ankib1在制备促进神经再生和修复神经损伤药物中的应用
MX2022000128A (es) 2019-06-27 2022-04-27 Scipher Medicine Corp Desarrollo de clasificadores para estratificar pacientes.
IL300978A (en) * 2020-09-01 2023-04-01 Scipher Medicine Corp Methods and systems for predicting response to anti-TNF treatments
US12379368B2 (en) * 2020-09-11 2025-08-05 Washington University Methods for determining therapeutic responsiveness for inflammatory bowel disease therapy
CN112180082B (zh) * 2020-09-27 2022-03-08 西安交通大学 Tweak在制备红斑狼疮诊断试剂中的应用
RU2749247C1 (ru) * 2020-09-28 2021-06-07 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Способ прогнозирования эффективности лечения ревматоидного артрита препаратом олокизумаб на основе генотипирования

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499052A (en) 1982-08-30 1985-02-12 Becton, Dickinson And Company Apparatus for distinguishing multiple subpopulations of cells
US4582789A (en) 1984-03-21 1986-04-15 Cetus Corporation Process for labeling nucleic acids using psoralen derivatives
US4563417A (en) 1984-08-31 1986-01-07 Miles Laboratories, Inc. Nucleic acid hybridization assay employing antibodies to intercalation complexes
SE458968B (sv) 1987-06-16 1989-05-22 Wallac Oy Biospecifikt analysfoerfarande foer flera analyter i vilket ingaar partikelraekning och maerkning med fluorescerande maerksubstanser
DK641487A (da) 1987-12-07 1989-06-08 Gluetech Aps Fremgangsmaade til modificering af polymeroverflader
US5871928A (en) 1989-06-07 1999-02-16 Fodor; Stephen P. A. Methods for nucleic acid analysis
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
DE69132905T2 (de) 1990-12-06 2002-08-01 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Detektion von Nukleinsäuresequenzen
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
FI955798A7 (fi) 1993-06-03 1996-02-01 Therapeutic Antibodies Inc Terapeuttiset vasta-ainefrangmentit
US6027880A (en) 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
FR2707882B1 (fr) 1993-07-23 1997-08-01 Immunotech Sa Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US5981180A (en) 1995-10-11 1999-11-09 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
US6057100A (en) 1996-06-07 2000-05-02 Eos Biotechnology, Inc. Oligonucleotide arrays
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US7473528B2 (en) * 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US6410231B1 (en) 1999-02-26 2002-06-25 Incyte Genomics, Inc. SNP detection
DE60040603D1 (de) 1999-08-17 2008-12-04 Luminex Corp Verfahren zur analyse einer mehrzahl von proben verschiedenen ursprungs auf einen analyten
JP2003515149A (ja) 1999-11-26 2003-04-22 キュラジェン コーポレイション 核酸プローブアレイ
CN1441677A (zh) 2000-03-31 2003-09-10 Idec药物公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
WO2002046378A2 (en) * 2000-12-08 2002-06-13 Juan Saus Alternative pol k nucleotide and amino acid sequence and methods for using
US7101663B2 (en) 2001-03-02 2006-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education PCR method
WO2002085926A2 (de) 2001-04-19 2002-10-31 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays
US6812341B1 (en) 2001-05-11 2004-11-02 Ambion, Inc. High efficiency mRNA isolation methods and compositions
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
WO2003062792A2 (en) * 2002-01-22 2003-07-31 Trustees Of The University Of Pennsylvania Methods for determining drug responsiveness
WO2004019277A1 (en) 2002-08-20 2004-03-04 Cyvera Corporation Diffraction grating-based encoded micro-particles for multiplexed experiments
US7190522B2 (en) 2002-09-12 2007-03-13 Cyvera Corporation Chemical synthesis using diffraction grating-based encoded optical elements
US7252976B2 (en) 2002-08-28 2007-08-07 Board Of Regents The University Of Texas System Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
KR20050058486A (ko) 2002-08-30 2005-06-16 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 인간형 항인간 인터루킨-6 항체 및 항체 단편
CA2499046A1 (en) 2002-09-12 2004-03-25 Cyvera Corporation Diffraction grating-based encoded micro-particles for multiplexed experiments
US7092160B2 (en) 2002-09-12 2006-08-15 Illumina, Inc. Method of manufacturing of diffraction grating-based optical identification element
EP1540590A1 (de) 2002-09-12 2005-06-15 Cyvera Corporation Kodierte mikrokugeln enthaltendes versuchsstäbchen
AU2003278827A1 (en) 2002-09-12 2004-04-30 Cyvera Corp. Method and apparatus for labelling using diffraction grating-based encoded optical identification elements
CA2498933C (en) 2002-09-12 2012-08-28 Cyvera Corporation Method and apparatus for aligning elongated microbeads in order to interrogate the same
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP4685369B2 (ja) * 2004-04-30 2011-05-18 独立行政法人科学技術振興機構 関節リウマチ診断用試薬
US20060008823A1 (en) 2004-05-12 2006-01-12 Kemp Jennifer T DNA profiling and SNP detection utilizing microarrays
GB0422417D0 (en) * 2004-10-08 2004-11-10 Ihg Diagnostics Improvements in induced heteroduplex generators
GT200500283A (es) * 2004-10-08 2006-05-08 Inmunoterapia de desordenes autoinmunes
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
JP2008546387A (ja) * 2005-06-13 2008-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
CN100338228C (zh) * 2005-06-30 2007-09-19 卫生部北京医院 一种预测2型糖尿病易感性的试剂
EP1929043A4 (de) * 2005-08-24 2009-10-28 Genizon Biosciences Inc Genkarte der mit morbus crohn assoziierten menschlichen gene
WO2007038501A2 (en) * 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers
EP1857559A1 (de) * 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur Vorhersage der Sensivität gegenüber TNF-alpha-Blockern
US20080293582A1 (en) * 2006-08-30 2008-11-27 Xilin Li Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel
WO2008132176A2 (en) * 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy

Also Published As

Publication number Publication date
CA2690898A1 (en) 2008-12-18
AU2008261869A1 (en) 2008-12-18
US20100303813A1 (en) 2010-12-02
CN103710458A (zh) 2014-04-09
EP2167687B1 (de) 2013-03-27
KR20100037590A (ko) 2010-04-09
NZ581742A (en) 2012-09-28
BRPI0812461A2 (pt) 2017-06-13
CN101796197B (zh) 2014-02-12
IL202562A0 (en) 2011-08-01
JP2010529464A (ja) 2010-08-26
JP2014033676A (ja) 2014-02-24
EA200971131A1 (ru) 2010-06-30
EP2167687A2 (de) 2010-03-31
AU2008261869B2 (en) 2014-12-18
EP2167687A4 (de) 2010-10-13
WO2008154423A2 (en) 2008-12-18
SG182183A1 (en) 2012-07-30
EA017815B1 (ru) 2013-03-29
JP5719591B2 (ja) 2015-05-20
EP2617837A3 (de) 2013-10-23
MX2009013410A (es) 2010-03-22
ZA200909215B (en) 2010-09-29
WO2008154423A3 (en) 2009-02-05
CN101796197A (zh) 2010-08-04
IL223419A0 (en) 2013-02-03
EP2617837A2 (de) 2013-07-24

Similar Documents

Publication Publication Date Title
NO20093488L (no) Biomarkorer for a predikere anti-TNF respons eller ikke-respons
MX2009009261A (es) Anticuerpos anti-ip-10 y metodos para su uso.
Dealberto Ethnic origin and increased risk for schizophrenia in immigrants to countries of recent and longstanding immigration
MY150709A (en) Human cytomegalovirus neutralising antibodies and use thereof
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
TW200740844A (en) Novel MAdCAM antibodies
MX2014006158A (es) Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa.
NO20073882L (no) Human anti-interferon gamma antistoffer og fremgangsmater for anvendelser derav
NO20063197L (no) Mutanter av anti-CD40 antistoff
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
ATE469658T1 (de) Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
TW200605907A (en) Preventing autoimmune disease
Dunger et al. Can we identify adolescents at high risk for nephropathy before the development of microalbuminuria?
SI1631312T1 (sl) Sestavki in postopki za terapijo vnetnih bolezni debelega äśrevesa
TW200716172A (en) Pharmaceutical compositions for treating lower motor neuron diseases
WO2008048902A8 (en) Methods of using single nucleotide polymorphisms in the il23r gene to predict or diagnose inflammatory bowel disease
WO2007022374A3 (en) Assessing response to anti-cd20 therapy by genotyping c1q components
HK1142929A (en) Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
American Occupational Therapy Association AOTA’s societal statement on livable communities
Brunetti et al. P232 Endogenous serum immunoglobulin levels in hospitalized patients
Kim Factors influencing life satisfaction in Korean baby-boomer men with drinking problems
Park et al. Research trends in preschool childhood language impairment during the last 10 years
Taniguchi et al. 77-P: HIGHER RISK OF KIDNEY GRAFT FAILURE AFTER REJECTION IN THE PRESENCE OF ANTIBODIES AGAINST ANGIOTENSIN II TYPE 1 RECEPTOR (AT1R)
Lefaucheur et al. P001 Changes in anti-HLA antibody complement-binding capacity reflect the efficacy of antibody-mediated rejection therapy and predict kidney allograft survival
Ekpanyaskul Sick building syndrome.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application